Copyright
©The Author(s) 2021.
World J Gastroenterol. Jun 7, 2021; 27(21): 2795-2817
Published online Jun 7, 2021. doi: 10.3748/wjg.v27.i21.2795
Published online Jun 7, 2021. doi: 10.3748/wjg.v27.i21.2795
Table 16 Medications and constipation
Ref. | Location | Sample size | Age range (yr) | Definition of constipation | Medications | Prevalence (%) | Odds ratio (95%CI) | P value |
Fosnes et al[54], 2011 | Norway | 4622 | 31-76 | Rome II | Digoxin; GTN; Furosemide; Atorvastatin; Tibolone; Levothyroxine; Ibuprofen | NR | NR | 0.025; 0.015; 0.001; 0.037; 0.038; < 0.001; 0.001 |
Talley et al[49], 1993 | United States | 690 | 30-64 | Rome I | Aspirin > 7 tabs/wk | 31.1 | 2.6 (1.2, 5.7) | < 0.05 |
Chang et al[46], 2007 | United States | 523 | 30-64 | Rome III | Paracetamol; Aspirin; NSAIDs | 25.3; 23.0; 26.6 | 1.50 (0.91, 2.47) 1.67 (1.04, 2.70) 1.80 (1.09, 2.98) | NS; < 0.05; < 0.05 |
- Citation: Werth BL, Christopher SA. Potential risk factors for constipation in the community. World J Gastroenterol 2021; 27(21): 2795-2817
- URL: https://www.wjgnet.com/1007-9327/full/v27/i21/2795.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i21.2795